STOCK TITAN
  1. Home
  2. News
  3. AKRO

Akero Therapeutics, Inc. - AKRO STOCK NEWS

Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.

Akero Therapeutics, Inc. (Nasdaq: AKRO) is a clinical-stage biotechnology company based in South San Francisco, developing innovative treatments for major metabolic diseases, including non-alcoholic steatohepatitis (NASH). Focused on creating best-in-class medicines, Akero's lead clinical program centers on efruxifermin (EFX), a modified FGF21 protein designed to reduce liver fat, inflammation, and fibrosis. EFX is engineered to target both the liver and adipose tissue, offering potential comprehensive benefits to NASH patients.

Building on over two decades of FGF21 research, Akero has achieved significant milestones. Their Phase 2b HARMONY study, evaluating EFX in pre-cirrhotic NASH patients, demonstrated impressive results at Week 96, including substantial fibrosis improvement and liver health biomarkers. Additionally, the SYNCHRONY program encompasses multiple Phase 3 clinical trials aimed at both cirrhotic and pre-cirrhotic NASH patients, further validating the efficacy and safety profile of EFX.

Akero's rigorous clinical trials and outstanding engagement with the FDA underscore their commitment to addressing high unmet medical needs. Their recent public stock offering has bolstered financial stability, ensuring sustained progress in their groundbreaking research and development efforts. For more information, visit Akero Therapeutics and follow them on LinkedIn and Twitter.

News

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

Rhea-AI Summary
Akero Therapeutics, Inc. (AKRO) will present clinical data from its HARMONY study after 96 weeks of treatment for pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients. The investor webcast is scheduled for March 4 at 8:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
conferences clinical trial
-
News

Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Akero Therapeutics, Inc. reported Q4 and full year financial results for 2023, with significant updates on their Phase 3 SYNCHRONY program and Phase 2b SYMMETRY study. They initiated two Phase 3 studies and reported promising results in the Phase 2b study. Financially, Akero's cash reserves are strong, supporting operations until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
earnings
-
News

Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Akero Therapeutics, Inc. (Nasdaq: AKRO) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 09:45 a.m. P.T. in San Francisco, CA. The company is focused on developing transformational treatments for patients with serious metabolic diseases with high unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
conferences
News

Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program

Rhea-AI Summary
Akero Therapeutics, Inc. (Nasdaq: AKRO) has reported the initiation of Phase 3 trials for their drug Efruxifermin (EFX) in patients with pre-cirrhotic NASH/MASH and compensated cirrhosis. The company is also planning an End-of-Phase 2 FDA meeting and expects to release the results of the Phase 2b HARMONY study in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
clinical trial
-
News

Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Akero Therapeutics, Inc. (Nasdaq: AKRO) reports third quarter financial results and business updates, including progress on Phase 3 SYNCHRONY studies for patients with NASH. The company is encouraged by the clinical development of EFX for pre-cirrhotic and cirrhotic NASH, with screening for the studies actively underway and on track for enrollment by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
earnings
-
News

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023

Rhea-AI Summary
Akero Therapeutics, Inc. (Nasdaq: AKRO) announced 36-week data from the SYMMETRY study, showing EFX's activity in patients with advanced cirrhosis due to NASH/MASH. Subgroup analysis revealed 22% and 10% improvement in fibrosis without NASH worsening in the 50mg and 28mg dose groups, respectively. The company will present the data at The Liver Meeting® 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
conferences
News

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

Rhea-AI Summary
Akero Therapeutics, Inc. (AKRO) to present at Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference. Live webcasts and archived replays will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
conferences
-
News

Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

Rhea-AI Summary
Akero Therapeutics to present at H.C. Wainwright 7th Annual NASH Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
conferences
-
News

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

Rhea-AI Summary
Akero Therapeutics reports positive results for efruxifermin in patients with cirrhosis due to NASH
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-62.61%
Tags
clinical trial
News

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Rhea-AI Summary
Akero Therapeutics to present clinical data in investor webcast
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-62.61%
Tags
conferences clinical trial

FAQ

What is the current stock price of Akero Therapeutics (AKRO)?

The current stock price of Akero Therapeutics (AKRO) is $29.34 as of December 20, 2024.

What is the market cap of Akero Therapeutics (AKRO)?

The market cap of Akero Therapeutics (AKRO) is approximately 2.0B.

What is Akero Therapeutics' main focus?

Akero Therapeutics focuses on developing treatments for serious metabolic diseases, primarily non-alcoholic steatohepatitis (NASH).

What is efruxifermin (EFX)?

Efruxifermin (EFX) is Akero's lead product, a modified FGF21 protein designed to reduce liver fat, inflammation, and fibrosis in NASH patients.

What are the key results from the HARMONY study?

The HARMONY study showed significant improvements in fibrosis and liver health biomarkers at Week 96 in patients treated with EFX.

What is the SYNCHRONY program?

The SYNCHRONY program includes Phase 3 clinical trials evaluating EFX in both cirrhotic and pre-cirrhotic NASH patients to further assess efficacy and safety.

How is Akero Therapeutics funded for their research?

Akero recently completed a public stock offering, raising substantial funds to support ongoing and future clinical trials and research efforts.

What is the significance of Akero's work with the FDA?

Akero's engagement with the FDA helps ensure regulatory compliance and accelerates the path towards potential approval of their treatments for NASH.

Where is Akero Therapeutics headquartered?

Akero Therapeutics is headquartered in South San Francisco, California.

How can I get more information about Akero Therapeutics?

Visit their website at akerotx.com and follow them on LinkedIn and Twitter for the latest updates and information.

Stock AKRO logo
Akero Therapeutics, Inc.

Nasdaq:AKRO

AKRO Rankings

#1974 Ranked by Market Cap
N/A Ranked by Dividends

AKRO Stock Data

1.98B
59.15M
5.33%
105.4%
5.19%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO